IL103269A - Anti-GFMH antibodies and the process for their production - Google Patents
Anti-GFMH antibodies and the process for their productionInfo
- Publication number
- IL103269A IL103269A IL103269A IL10326992A IL103269A IL 103269 A IL103269 A IL 103269A IL 103269 A IL103269 A IL 103269A IL 10326992 A IL10326992 A IL 10326992A IL 103269 A IL103269 A IL 103269A
- Authority
- IL
- Israel
- Prior art keywords
- derived
- light chain
- residues
- human
- antibody molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919120467A GB9120467D0 (en) | 1991-09-26 | 1991-09-26 | Anti-hmfg antibodies and process for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL103269A0 IL103269A0 (en) | 1993-02-21 |
| IL103269A true IL103269A (en) | 1998-01-04 |
Family
ID=10701993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL103269A IL103269A (en) | 1991-09-26 | 1992-09-24 | Anti-GFMH antibodies and the process for their production |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6506881B1 (fr) |
| EP (2) | EP0781845B1 (fr) |
| JP (1) | JP3498957B2 (fr) |
| AT (2) | ATE160362T1 (fr) |
| AU (1) | AU666868B2 (fr) |
| CA (1) | CA2095926C (fr) |
| DE (2) | DE69223206T2 (fr) |
| DK (1) | DK0781845T3 (fr) |
| ES (1) | ES2108732T3 (fr) |
| GB (1) | GB9120467D0 (fr) |
| IL (1) | IL103269A (fr) |
| NZ (1) | NZ244468A (fr) |
| WO (1) | WO1993006231A1 (fr) |
Families Citing this family (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU5615594A (en) * | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
| DE69332930T2 (de) * | 1992-11-16 | 2004-02-26 | Cancer Research Fund Of Contra Costa, Walnut Creek | Peptide mit breiter neoplastischer spezifizität |
| US6281335B1 (en) * | 1993-10-08 | 2001-08-28 | Coulter Corporation | Hybridoma and anti-KC-4 humanized monoclonal antibody |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| ATE370235T1 (de) * | 1994-09-16 | 2007-09-15 | Cancer Res Fund Of Contra Cost | Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden |
| US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| NZ568033A (en) | 1998-11-27 | 2011-04-29 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
| WO2001074905A1 (fr) * | 2000-04-03 | 2001-10-11 | Antisoma Research Limited | Composes de ciblage |
| CA2406884C (fr) | 2000-04-21 | 2009-02-17 | Fuso Pharmaceutical Industries, Ltd. | Nouvelles collectines |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| US20020147312A1 (en) * | 2001-02-02 | 2002-10-10 | O'keefe Theresa | Hybrid antibodies and uses thereof |
| US6441163B1 (en) * | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
| EP1534753B1 (fr) | 2002-05-28 | 2011-08-03 | UCB Pharma, S.A. | Isomeres de position de peg d'un anticorps contre le tnfalpha (cdp870) |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| BRPI0619595B8 (pt) | 2005-12-09 | 2022-12-13 | Ucb Pharma Sa | anticorpo neutralizante, sequência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção de um anticorpo, composição farmacêutica, e, uso de um anticorpo neutralizante humanizado |
| CA2646391A1 (fr) | 2006-03-22 | 2007-09-27 | Viral Logic Systems Technology Corp. | Procedes d'identification de polypeptides cibles et utilisations dans le traitement de maladies immunologiques |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| US20080118518A1 (en) * | 2006-09-07 | 2008-05-22 | Cirrito Thomas P | Cancer stem cell-targeted cancer therapy |
| GB0620729D0 (en) | 2006-10-18 | 2006-11-29 | Ucb Sa | Biological products |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
| EP2283862B1 (fr) * | 2008-06-02 | 2018-08-08 | The University of Tokyo | Thérapie combinée contenant des anticorps contre mfg-e8 pour le traitement du cancer |
| EP2145901B1 (fr) * | 2008-07-18 | 2012-11-14 | Technische Universität Braunschweig | Anticorps recombinants anti-MUC1 |
| SG2014014708A (en) | 2009-02-17 | 2014-05-29 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| WO2011030107A1 (fr) | 2009-09-10 | 2011-03-17 | Ucb Pharma S.A. | Anticorps multivalents |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| WO2011110604A1 (fr) | 2010-03-11 | 2011-09-15 | Ucb Pharma, S.A. | Anticorps pd-1 |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| EP2550297B1 (fr) | 2010-03-25 | 2019-01-23 | UCB Biopharma SPRL | Molécules de dvd-lg stabilisées par un disulfure |
| GB201012599D0 (en) | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Process for purifying proteins |
| GB201014033D0 (en) | 2010-08-20 | 2010-10-06 | Ucb Pharma Sa | Biological products |
| MA34907B1 (fr) | 2011-01-14 | 2014-02-01 | Ucb Pharma Sa | Molécules d'anticorps se liant à il-17a et il-17f |
| CN108424449A (zh) | 2011-09-16 | 2018-08-21 | Ucb医药有限公司 | 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| GB201203071D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201203051D0 (en) | 2012-02-22 | 2012-04-04 | Ucb Pharma Sa | Biological products |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201223276D0 (en) | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| GB201320066D0 (en) | 2013-11-13 | 2013-12-25 | Ucb Pharma Sa | Biological products |
| GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| WO2016176656A2 (fr) | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Anticorps anti-ap2 et agents de liaison à l'antigène utilisables en vue du traitement d'affections métaboliques |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
| WO2016189045A1 (fr) | 2015-05-27 | 2016-12-01 | Ucb Biopharma Sprl | Méthode pour le traitement d'une maladie neurologique |
| BR112017028102A2 (pt) | 2015-07-06 | 2018-09-04 | Ucb Biopharma Sprl | anticorpos de ligação à tau |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| CN108350068A (zh) | 2015-10-27 | 2018-07-31 | Ucb生物制药私人有限公司 | 使用抗-il-17a/f抗体的治疗方法 |
| GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
| GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
| GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| US11534496B2 (en) | 2016-06-07 | 2022-12-27 | The Brigham And Women's Hospital, Inc. | Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions |
| GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
| JP2020500834A (ja) | 2016-08-26 | 2020-01-16 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用 |
| GB201616596D0 (en) | 2016-09-29 | 2016-11-16 | Nascient Limited | Epitope and antibodies |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| WO2018183366A1 (fr) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Polythérapies d'anticorps csf-1r ou csf-1 et thérapie reposant sur des lymphocytes t |
| CN111278459A (zh) | 2017-05-19 | 2020-06-12 | 赛达克斯制药股份有限公司 | 组合疗法 |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| SG11202103801UA (en) | 2018-10-16 | 2021-05-28 | UCB Biopharma SRL | Method for the treatment of myasthenia gravis |
| AU2020247175A1 (en) | 2019-03-26 | 2021-10-14 | Aslan Pharmaceuticals Pte Ltd | Treatment employing anti-IL-13R antibody or binding fragment thereof |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| GB201919058D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibodies |
| GB201919061D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Multi-specific antibody |
| GB202001447D0 (en) | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| IL301859A (en) | 2020-10-15 | 2023-06-01 | UCB Biopharma SRL | Binding molecules for CD45 multimerization |
| JP2023550596A (ja) | 2020-11-02 | 2023-12-04 | ユーシービー バイオファルマ エスアールエル | 運動ニューロン神経変性障害の治療のための抗ｔｒｅｍ１中和抗体の使用 |
| US20240067758A1 (en) | 2020-12-07 | 2024-02-29 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
| EP4255925A1 (fr) | 2020-12-07 | 2023-10-11 | UCB Biopharma SRL | Anticorps contre l'interleukine-22 |
| WO2022186773A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ CHEZ UNE POPULATION ALLERGIQUE |
| WO2022186772A1 (fr) | 2021-03-01 | 2022-09-09 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DE LA DERMATITE ATOPIQUE À L'AIDE D'UN ANTICORPS ANTI-IL-13Rα1 OU D'UN FRAGMENT DE LIAISON ASSOCIÉ |
| EP4067381A1 (fr) | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Nouvelles molécules de liaison tnfr2 |
| CA3218933A1 (fr) | 2021-05-03 | 2022-11-10 | UCB Biopharma SRL | Anticorps |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| WO2023048651A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | Procédé de traitement de la dermatite atoptique modérée à grave |
| WO2023048650A1 (fr) | 2021-09-27 | 2023-03-30 | Aslan Pharmaceuticals Pte Ltd | TRAITEMENT DU PRURIT FAISANT INTERVENIR UN ANTICORPS ANTI-IL13Rα1 OU UN FRAGMENT DE LIAISON DE CELUI-CI |
| GB202115122D0 (en) | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
| TW202333784A (zh) | 2021-10-29 | 2023-09-01 | 新加坡商亞獅康私人有限公司 | 抗ｉｌ１３ｒ抗體調配物 |
| WO2023140780A1 (fr) | 2022-01-24 | 2023-07-27 | Aslan Pharmaceuticals Pte Ltd. | Procédé de traitement de maladie inflammatoire |
| TW202337905A (zh) | 2022-02-23 | 2023-10-01 | 新加坡商亞獅康私人有限公司 | 抗il13r抗體之糖基化形式 |
| GB202210679D0 (en) | 2022-07-21 | 2022-09-07 | Dualyx Nv | Binding molecules targeting il-12rb2 |
| WO2024043837A1 (fr) | 2022-08-26 | 2024-02-29 | Aslan Pharmaceuticals Pte Ltd | Formulation d'anticorps anti-il13r à haute concentration |
| WO2024054157A1 (fr) | 2022-09-06 | 2024-03-14 | Aslan Pharmaceuticals Pte Ltd | Traitement de la perte de sommeil ou des troubles du sommeil chez des patients atteints de dermatite |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2584293B1 (fr) * | 1985-07-04 | 1989-03-17 | Ire Celltarg Sa | Anticorps utiles comme agents de pilotage et conjugues les incorporant |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL115770A (en) * | 1989-04-14 | 1999-03-12 | American Cyanamid Co | Substituted disulfides of formula q-sp-ss-w their preparation and use for inhibiting the growth of tumours and for treating bacterial infections |
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
-
1991
- 1991-09-26 GB GB919120467A patent/GB9120467D0/en active Pending
-
1992
- 1992-09-24 WO PCT/GB1992/001759 patent/WO1993006231A1/fr active Application Filing
- 1992-09-24 AT AT92308680T patent/ATE160362T1/de not_active IP Right Cessation
- 1992-09-24 AT AT97200482T patent/ATE236251T1/de not_active IP Right Cessation
- 1992-09-24 EP EP97200482A patent/EP0781845B1/fr not_active Expired - Lifetime
- 1992-09-24 IL IL103269A patent/IL103269A/en not_active IP Right Cessation
- 1992-09-24 EP EP92308680A patent/EP0534742B1/fr not_active Expired - Lifetime
- 1992-09-24 JP JP50593493A patent/JP3498957B2/ja not_active Expired - Lifetime
- 1992-09-24 CA CA002095926A patent/CA2095926C/fr not_active Expired - Lifetime
- 1992-09-24 DK DK97200482T patent/DK0781845T3/da active
- 1992-09-24 DE DE69223206T patent/DE69223206T2/de not_active Expired - Lifetime
- 1992-09-24 NZ NZ244468A patent/NZ244468A/en unknown
- 1992-09-24 ES ES92308680T patent/ES2108732T3/es not_active Expired - Lifetime
- 1992-09-24 DE DE69232991T patent/DE69232991T2/de not_active Expired - Lifetime
- 1992-09-24 AU AU25983/92A patent/AU666868B2/en not_active Expired
-
1995
- 1995-05-25 US US08/450,809 patent/US6506881B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0781845A2 (fr) | 1997-07-02 |
| DE69223206D1 (de) | 1998-01-02 |
| JPH06505399A (ja) | 1994-06-23 |
| CA2095926C (fr) | 2002-07-16 |
| ATE236251T1 (de) | 2003-04-15 |
| EP0534742B1 (fr) | 1997-11-19 |
| AU666868B2 (en) | 1996-02-29 |
| DE69232991T2 (de) | 2004-01-15 |
| ATE160362T1 (de) | 1997-12-15 |
| DE69223206T2 (de) | 1998-06-25 |
| EP0534742A1 (fr) | 1993-03-31 |
| EP0781845B1 (fr) | 2003-04-02 |
| NZ244468A (en) | 1994-11-25 |
| DK0781845T3 (da) | 2003-06-16 |
| EP0781845A3 (fr) | 1997-07-09 |
| GB9120467D0 (en) | 1991-11-06 |
| US6506881B1 (en) | 2003-01-14 |
| ES2108732T3 (es) | 1998-01-01 |
| AU2598392A (en) | 1993-04-27 |
| DE69232991D1 (de) | 2003-05-08 |
| IL103269A0 (en) | 1993-02-21 |
| JP3498957B2 (ja) | 2004-02-23 |
| WO1993006231A1 (fr) | 1993-04-01 |
| CA2095926A1 (fr) | 1993-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU666868B2 (en) | Anti-human milk fat globule humanised antibodies | |
| US6020145A (en) | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 | |
| US5980896A (en) | Antibodies reactive with human carcinomas | |
| FI108797B (fi) | Menetelmiä humanisoitujen immunoglobuliinien tuottamiseksi sekä menetelmissä käyttökelpoinen polynukleotidimolekyyli ja solulinja | |
| US6307026B1 (en) | Humanized antibodies directed against A33 antigen | |
| US9822183B2 (en) | CA6 antigen-specific cytotoxic conjugate and methods of using the same | |
| FI113243B (fi) | Menetelmä c-erbB-2(HER-2/neu):hen liittyviin pinta-antigeeneihin suunnattujen immunotoksiinien valmistamiseksi | |
| JP3066983B2 (ja) | 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体 | |
| EP1660513B1 (fr) | Conjugue cytotoxique specifique de l'antigene ca6 et procedes d'utilisation | |
| AU675057B2 (en) | Process for the preparation of transferrin receptor specificantibody-neuropharmaceutical or diagnostic agent conjugates | |
| US6287562B1 (en) | Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates | |
| EP0699756B1 (fr) | Anticorps BR96 mutantsréagissant aux carcinomes humains | |
| WO1989006692A1 (fr) | Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance | |
| US6015562A (en) | Targeted forms of methyltrithio antitumor agents | |
| EP0628077B1 (fr) | Anticorps humanises diriges contre l'antigene a33 | |
| WO1993012220A1 (fr) | ANTICORPS DE RECOMBINAISON ET CHIMERIQUES CONTRE c-erbB-2 | |
| AU2005335743A1 (en) | A CA6 antigen-specific cytotoxic conjugate and methods of using the same | |
| EP4215549A1 (fr) | Anticorps bispécifique anti-4-1bb-anti-pd-l1, composition pharmaceutique et utilisation associées | |
| RU2814164C2 (ru) | Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| HC | Change of name of proprietor(s) | ||
| RH1 | Patent not in force |